List of Tradjenta drug patents

Tradjenta is owned by Boehringer Ingelheim.

Tradjenta contains Linagliptin.

Tradjenta has a total of 10 drug patents out of which 0 drug patents have expired.

Tradjenta was authorised for market use on 02 May, 2011.

Tradjenta is available in tablet;oral dosage forms.

Tradjenta can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone), method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin, method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin, treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment, method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.

The generics of Tradjenta are possible to be released after 05 March, 2031.

TRADJENTA's oppositions filed in EPO
TRADJENTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(4 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(4 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(4 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using LINAGLIPTIN ingredient

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's patent expiration?
More Information on Dosage

TRADJENTA family patents

45

United States

34

Japan

34

European Union

27

China

24

Korea, Republic of

19

New Zealand

13

EA

12

Taiwan, Province of China

10

Mexico

10

Hong Kong

9

Malaysia

9

Brazil

9

Argentina

9

Canada

9

Australia

8

Spain

8

Peru

8

Poland

7

Germany

7

Norway

7

Chile

7

Denmark

6

Portugal

6

Croatia

6

Ukraine

5

Singapore

5

Uruguay

5

South Africa

5

Cyprus

5

Slovenia

5

ME

5

Ecuador

5

RS

3

Hungary

3

Israel

2

Philippines

2

Austria

2

India

2

Luxembourg

1

Turkey

1

Colombia

1

Egypt

1

Morocco

1

Belgium

1

Tunisia

1

Yugoslavia

1

Saudi Arabia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in